Cellular Immunotherapy Targets a Common Human Cancer Mutation

Anne Li                                                                                                Feburary 11th, 2016


In a study of an immune therapy for colorectal cancer that involved a single patient, a team of researchers at the National Cancer Institute (NCI) identified a method for targeting the cancer-causing protein produced by a mutant form of the KRAS gene. This targeted immunotherapy led to cancer regression in the patient in the study. The finding appeared Dec. 8, 2016, in the New England Journal of Medicine. The study was led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research, and was conducted at the NIH Clinical Center.
See original article at: https://www.cancer.gov/news-events/press-releases/2016/immunotherapy-targets-kras

Post a comment